This clinical trial is focused on studying obesity in teenagers. The treatment being tested is a medication called semaglutide, which is given as an injection under the skin using a pre-filled pen. The study aims to see how well semaglutide helps teenagers who have lost weight to maintain their weight loss over time. The medication is also known by its code name, NNC0113-0217, and is available in different doses, including 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg.

The purpose of the study is to investigate how effective semaglutide is in helping adolescents maintain a healthy weight after they have already achieved a body mass index (BMI) below the obesity threshold. Participants will receive the treatment for a period of up to six years, with the main focus on maintaining their weight loss from 1.5 years to 3 years. The study will also look at how the dose of semaglutide can be gradually reduced over time.

Throughout the study, participants will be monitored for changes in their BMI, waist circumference, and other health markers such as blood sugar levels and cholesterol. The study will also track any side effects or serious adverse events that may occur. The goal is to provide valuable information on the long-term use of semaglutide in managing obesity in teenagers.